Consumer medicine information

Nidem

Gliclazide

BRAND INFORMATION

Brand name

Nidem

Active ingredient

Gliclazide

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Nidem.

What is in this leaflet

This leaflet answers some common questions about NIDEM.

It does not contain all of the available information. It does not take the place of talking to your doctor, pharmacist or diabetes educator.

All medicines have benefits and risks. Your doctor has weighed the risks of you taking NIDEM against the benefits they expect it will have for you.

Talk to your doctor, pharmacist or diabetes educator if you have any concerns about taking this medicine.

Keep this leaflet with your medicine. You may need to read it again.

What NIDEM is used for

NIDEM is used to control blood glucose in people with Type 2 diabetes mellitus. This type of diabetes is also called non-insulin dependent diabetes mellitus (NIDDM) or maturity onset diabetes.

NIDEM is used when diet and exercise are not enough to control your blood glucose levels. It can be used alone, or in combination with other medicines for treating diabetes.

NIDEM is available only with a doctor's prescription.

How NIDEM works

NIDEM belongs to a group of medicines called sulphonylureas. These medicines lower blood glucose by increasing the amount of insulin produced by your pancreas.

If your blood glucose is not properly controlled, you may experience hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose).

Hypoglycaemia
Hypoglycaemia (low blood glucose) can occur suddenly. Signs may include:

  • weakness, trembling or shaking
  • sweating
  • lightheadedness, dizziness, headache or lack of concentration
  • irritability, tearfulness or crying
  • hunger
  • numbness around the lips and tongue.

If not treated promptly, these may progress to:

  • loss of co-ordination
  • slurred speech
  • confusion
  • fits or loss of consciousness

Hyperglycaemia
Hyperglycaemia (high blood glucose) usually occurs more slowly than hypoglycaemia. Signs of hyperglycaemia may include:

  • lethargy or tiredness
  • headache
  • thirst
  • passing large amounts or urine
  • blurred vision

Long-term hyperglycaemia can lead to serious health problems such as heart disease, blindness, poor blood circulation, gangrene, and kidney damage.

Before you take NIDEM

When you must not take it

Do not take this medicine if you are allergic to:

  • medicines containing gliclazide or any other sulphonylurea
  • sulfonamide (sulfur) antibiotics
  • certain types of fluid tablets (thiazide diuretics)
  • any of the ingredients listed at the end of this leaflet.

Do not take it if you have any of the following medical conditions:

  • type 1 diabetes mellitus that is well controlled by insulin alone
  • unstable diabetes that is not well controlled
  • diabetic acidosis
  • diabetic coma
  • severe kidney disease
  • you are taking an antibiotic medicine containing the active ingredient miconazole
  • severe liver disease.

Do not take it if you are pregnant or plan to become pregnant. Insulin is more suitable for controlling blood glucose during pregnancy. Your doctor will replace NIDEM with insulin while you are pregnant.

Do not take it if you are breastfeeding. This medicine can pass into breast milk and may harm your baby.

Do not take it if the expiry date (Exp.) printed on the pack has passed.

Do not take it if the packaging shows signs of tampering or the tablets do not look quite right.

If you are not sure whether you should start taking NIDEM, ask your doctor.

Before you start to take it

Tell your doctor if you are allergic to any other medicines, foods, dyes or preservatives.

Tell your doctor if you have any medical conditions, especially the following:

  • liver problems
  • kidney problems
  • a history of diabetic coma
  • heart failure
  • adrenal, pituitary or thyroid problems.
  • If you have a family history of or know you have the hereditary condition glucose-6- phosphate dehydrogenase (G6PD) deficiency (abnormality of red blood cells), lowering of the haemoglobin level and breakdown of red blood cells (haemolytic anaemia) can occur.
  • you have any medical condition, or do anything, that may increase the risk of hyperglycaemia - for example

Tell your doctor if you

  • drink alcohol in any amount
  • do not eat regular meals
  • do a lot of exercise
  • are ill or feeling unwell.
  • you are pregnant or plan to become pregnant or are breast- feeding.
    Your doctor can discuss with you the risks and benefits involved.

Alcohol, diet, exercise and your general health all strongly affect the control of your diabetes.
Discuss these with your doctor.

If you have not told your doctor about any of the above, tell them before you start taking NIDEM.

Taking other medicines

Tell your doctor if you are taking any other medicines, including any that you buy without a prescription from a pharmacy, supermarket or health food shop.

Some medicines may be affected by NIDEM or may affect how well it works. These include:

  • other medicines used to treat diabetes (such as biguanides and insulin)
  • some medicines used to treat fungal or yeast infections (miconazole which is contraindicated)
  • alcohol
  • medicines used to treat high blood pressure and some heart conditions
  • monoamine oxidase inhibitors (MAOIs), medicines used to treat depression
  • clofibrate, a medicine used to reduce high blood fat levels
  • medicines used to prevent blood clots
  • diuretics, also called fluid tablets
  • some antibiotics
  • cimetidine, a medicine used to treat reflux and ulcers
  • corticosteroids such as prednisone, cortisone
  • some medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis
  • oestrogens such as in oral contraceptives or hormone replacement therapy
  • barbiturates, medicines used to treat epilepsy.

Some medicines may lead to high blood glucose levels (hyperglycaemia) by weakening the blood glucose-lowering effect of Nidem

These include:

  • alcohol
  • some medicines for epilepsy (danazol)
  • some medicines used to treat depression and other mental illness (chlorpromazine)
  • some hormones used in hormone replacement therapy and oral contraceptives (oestrogen, progesterone)
  • St John's Wort (Hypericum perforatum) preparations used to treat depression
  • some medicines for asthma (salbutamol, intravenous terbutaline).
  • barbiturates, medicines used for sedation
  • glucocorticoids

Some medicines may lead to unstable blood glucose (low blood sugar and high blood sugar) when taken at the same time as NIDEM, especially in elderly patients.

These include:

  • A class of antibiotics called fluoroquinolones.

NIDEM may change the effects of some other medicines.

These include:

  • some medicines used to prevent blood clots (warfarin)

You may need different amounts of your medicine or you may need to take different medicines. Your doctor, pharmacist or diabetes educator can tell you what to do if you are taking any of these medicines. They also have a more complete list of medicines to be careful with or avoid while taking NIDEM.

Your doctor or pharmacist can tell you what to do if you are taking any of these medicines. They also have more information on medicines to be careful with or avoid while taking NIDEM.

Check with your doctor or pharmacist if you are not sure whether you are taking any of these medicines.

How to take it

How much to take

The dose varies from patient to patient. Your doctor will decide the right dose for you.

The usual starting dose for adults is half an 80 mg tablet each day.Your doctor may increase this dose up to four tablets a day, depending on your blood glucose levels.

How to take NIDEM

Swallow the tablets with a glass of water.

This medicine can be taken before, during or after food.

If you forget to take it

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Otherwise, take the missed dose as soon as you remember (with food), and then go back to taking your tablets as you would normally.

Do not take a double dose to make up for the dose you missed.

If you are not sure what to do, ask your doctor or pharmacist.

How long to take it for

Keep taking NIDEM for as long as your doctor recommends.

This medicine will help control diabetes but will not cure it. Most people will need to take NIDEM for long periods of time.

If you take too much (overdose)

Immediately telephone your doctor, or the Poisons Information Centre (telephone 13 11 26), or go to Accident and Emergency at the nearest hospital, if you think you or anyone else may have taken too much NIDEM. Do this even if there are no signs of discomfort or poisoning.

If you take too much medicine, you may experience symptoms of hypoglycaemia (low blood glucose).

If you do experience any signs of hypoglycaemia, raise your blood glucose quickly by eating jelly beans, sugar or honey, drinking non-diet soft drink or taking glucose tablets.

While you are taking it

Things you must do

Before starting any new medicine, tell your doctor or pharmacist that you are taking NIDEM.

Tell all the doctors, dentists and pharmacists who are treating you that you are taking NIDEM.

If you become pregnant while taking this medicine, tell your doctor immediately.

Make sure that you, your friends, family and work colleagues can recognise the symptoms of hypoglycaemia and hyperglycaemia and know how to treat them.

Hypoglycaemia

If you experience any of the symptoms of hypoglycaemia, you need to raise your blood glucose immediately. You can do this by doing one of the following:

  • eating 5-7 jelly beans
  • eating 3 teaspoons of sugar or honey
  • drinking half a can of non-diet soft drink
  • taking 2-3 concentrated glucose tablets.

Unless you are within 10 to 15 minutes of your next meal or snack, follow up with extra carbohydrates such as plain biscuits, fruit or milk. Taking this extra carbohydrate will prevent a second drop in your blood glucose level.

Hyperglycaemia

If you experience any of the symptoms of hyperglycaemia, contact your doctor immediately.

The risk of hyperglycaemia is increased in the following situations:

  • uncontrolled diabetes
  • illness, infection or stress
  • taking less NIDEM than prescribed
  • taking certain other medicines
  • too little exercise
  • eating more carbohydrates than normal.

Tell your doctor if any of the following happen:

  • you become ill
  • you are injured
  • you have a fever
  • you have a serious infection
  • you are having surgery.

Your blood glucose may become difficult to control at these times.Your doctor may decide to replace NIDEM with insulin.

Visit your doctor regularly for check-ups. Your doctor may want to check your kidneys, liver, heart and blood while you are taking this medicine.

Make sure you check your blood glucose levels regularly. This is the best way to tell if your diabetes is being controlled properly. Your doctor or diabetes educator will show you how and when to do this.

Carefully follow your doctor's and dietician’s advice on diet, drinking alcohol and exercise. If you drink alcohol while taking this medicine, you may get flushing, headache, breathing difficulties, rapid heartbeat, stomach pains or feel sick and vomit. The combination of alcohol and NIDEM also increases the risk of hypoglycaemia occurring.

Tell your doctor immediately if you notice the return of any symptoms of hyperglycaemia you have experienced before starting NIDEM. These may include lethargy or tiredness, headache, thirst, passing large amounts of urine and blurred vision. These may be signs that this medicine is no longer working, even though you may have been taking it successfully for some time.

Things you must not do

Do not skip meals while taking NIDEM.

Do not stop taking it or change the dose without checking with your doctor.

Do not give it to anyone else, even if they have the same condition as you.

Things to be careful of

Be careful driving or operating machinery until you know how this medicine affects you. NIDEM may cause dizziness in some people. Drinking alcohol can make this worse. If either of these occur, do not drive, operate machinery or do anything else that could be dangerous.

If you drink alcohol while taking NIDEM, you may get flushing, headache, breathing difficulties, rapid heart beat, stomach pains or feel sick and vomit.

Be careful not to let your blood glucose levels fall too low. Low blood glucose levels may slow your reaction time and affect your ability to drive or operate machinery.

If you become sick with a cold, fever or flu, it is very important to continue taking NIDEM and eating your normal meals. If you have trouble eating solid food, use sugar-sweetened drinks as a carbohydrate substitute or eat small amounts of bland food. Your diabetes educator or dietician can give you a list of foods to eat on sick days.

When you are travelling, it is a good idea to:

  • wear some form of identification (e.g. bracelet) showing you have diabetes
  • carry some form of sugar to treat hypoglycaemia if it occurs, for example, sugar sachets or jelly beans
  • carry emergency food rations in case of a delay, for example, dried fruit, biscuits or muesli bars
  • bring enough NIDEM with you, so you don't miss any doses.

Protect your skin when you are in the sun, especially between 10am and 3pm. Sulphonylureas (the group of medicines that NIDEM belongs to) may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight may cause a skin rash, itching, redness, or a severe sunburn.

If outdoors, wear protective clothing and use a 30+ sunscreen. If your skin does appear to be burning, tell your doctor immediately.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking NIDEM.

NIDEM helps most people with diabetes but it may have unwanted side effects in some people.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

NIDEM helps most people with Type 2 diabetes, but it may sometimes have unwanted side effects. These can include:

  • hyPOglycaemia and hyPERglycaemia. A section at the end of this leaflet contains advice about recognising and treating hyPOglycaemia and hyPERglycaemia
  • runny or blocked nose, sneezing, facial pressure or pain, bronchitis, sore throat and discomfort when swallowing, upper respiratory infection, coughing
  • back pain, arthralgia, arthrosis,
  • high blood pressure, chest pain,
  • Headache, unusual weakness,
  • Viral infection, urinary tract infection,
  • dizziness
  • decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. These symptoms usually vanish when the treatment is discontinued
  • Increase of some hepatic enzymes levels, and exceptionally a liver disease,
  • your vision may be affected for a short time especially at the start of treatment. This effect is due to changes in blood sugar levels.

Ask your doctor or pharmacist to answer any questions you may have.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

Tell your doctor if you notice any of the following and they worry you:

  • stomach upset such as feeling sick (nausea), heartburn
  • constipation or a feeling of fullness in the stomach
  • headache
  • tiredness.

Tell your doctor immediately if you notice any of the following symptoms:

  • Skin rash, redness itching and/ or hives, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. The rash may progress to widespread blistering or peeling of the skin and may be the first sign of rare life threatening conditions (e.g Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and severe hypersensitivity reactions (DRESS).
  • As for other sulphonylureas, the following adverse events have been observed: cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (e.g. jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases

Other side effects not listed above may also occur in some people. Tell your doctor if you notice anything that is making you feel unwell.

After using it

Storage

Keep your medicine where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Keep your tablets in a cool dry place where the temperature stays below 30°C.

Do not store NIDEM or any other medicine in the bathroom or near a sink.

Do not leave it in the car or on window sills. Heat and dampness can destroy some medicines.

Disposal

If your doctor tells you to stop taking NIDEM, or your tablets have passed their expiry date, ask your pharmacist what to do with any that are left over.

Product description

What it looks like

NIDEM is a white to off white round, bevel-edged, uncoated tablet with cross score (+) on one face and plain on the other.

Each pack contains 100 tablets.

Ingredients

The active ingredient in NIDEM is gliclazide. Each NIDEM tablet contains 80 mg of gliclazide.

The tablets also contain:

  • lactose monohydrate
  • microcrystalline cellulose
  • povidone
  • sodium starch glycollate type A
  • purified talc
  • magnesium stearate.

The tablets do not contain gluten, sucrose, tartrazine or any other azo dyes.

The tablets contain sugars as lactose.

Sponsor

Arrow Pharma Pty Ltd
15-17 Chapel Street
Cremorne VIC 3121
Australia

Australian registration number: NIDEM – AUST R 79023

Recognising and treating hyPOglycaemia (very LOW blood sugar levels)

Hypoglycaemia may occur during NIDEM treatment.

The first signs of hypoglycaemia are usually weakness, trembling or shaking, sweating, lightheadedness, dizziness, headache or lack of concentration, irritability, tearfulness,hunger, and/ or numbness around the lips and tongue.

At the first signs of hypoglycaemia take some sugar to raise your blood sugar level quickly. Do this by eating 5 to 7 jelly beans, 3 teaspoons of sugar or honey, drinking half a can of non-diet soft drink, taking 2-3 glucose tablets or a tube of glucose gel.

Then take some extra carbohydrates
such as plain biscuits, fruit or milk - unless you are within 10-15 minutes of your next meal. Taking this extra carbohydrate will help to prevent a second drop in your blood glucose level.

If not treated quickly,
hypoglycaemia symptoms may progress to loss of co-ordination, slurred speech, confusion, fits or loss of consciousness.

If hypoglycaemia symptoms do not get better straight away after taking sugar then go to the Accident and Emergency department at your nearest hospital - if necessary by calling an ambulance.

Contact your doctor or diabetes educator for advice if you are concerned about hypoglycaemia.

Recognising and treating hyPERglycaemia (HIGH blood sugar levels)

Some people may feel fine when their glucose levels are high. Others notice symptoms of hyperglycaemia like tiredness, lack of energy, thirst, passing large amounts of urine, headache, and/or blurred vision.

If you notice symptoms of hyperglycaemia , or your blood sugar levels are high, tell your doctor immediately. You may need adjustments of the dose or type of medicines you are taking.

It is very important to control high blood glucose whether or not you feel unwell. This really helps to avoid serious long-term health Problems, which can involve the heart, eyes, circulation, and/or kidneys.

If you experience any of the signs of hyperglycaemia (high blood glucose) contact your doctor or diabetes educator for advice immediately

This leaflet was last revised in November 2021.

Published by MIMS January 2022

BRAND INFORMATION

Brand name

Nidem

Active ingredient

Gliclazide

Schedule

S4

 

1 Name of Medicine

Gliclazide.

2 Qualitative and Quantitative Composition

Nidem tablets contain 80 mg of gliclazide.

Excipients with known effect.

Lactose monohydrate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Uncoated tablets.
A white to off white round, bevel-edged, uncoated tablet with cross score (+) on one face and plain on the other.

4 Clinical Particulars

4.1 Therapeutic Indications

Diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone.

4.2 Dose and Method of Administration

For adult use only.
The dosage of gliclazide should be carefully titrated to maintain optimal control at the various possible dose levels. Dosage should be initiated at 40 mg (½ tablet) daily and may be increased if necessary up to 320 mg (four tablets) daily. Doses up to 160 mg daily may be taken in a single dose but preferably at the same time each morning. Doses in excess of 160 mg should be taken in divided doses in the morning and evening.
In general, the dosage will depend on the severity of the glycaemia with ongoing adjustments made in order to obtain the optimal response at the lowest dosage.
Treatment with gliclazide does not obviate the necessity of maintaining standard dietary regulations.

4.3 Contraindications

Gliclazide should not be used in diabetes complicated by acidosis, ketosis or coma or in patients with a history of repeated episodes of ketoacidosis or coma.
Juvenile onset diabetes and unstable or brittle diabetes. As sulfonylurea hypoglycaemic agents are not effective in juvenile onset, unstable or brittle diabetes, gliclazide should not be used in these conditions.

Hypersensitivity.

Gliclazide should not be used with patients with known sensitivity to sulfonylureas.

Impaired renal function.

Gliclazide is contraindicated in severe renal insufficiency. Caution should be exercised and dosage reduction may be required when using gliclazide in patients with impaired renal function.

Impaired hepatic function.

Gliclazide is contraindicated in severe hepatic insufficiency. Caution should be exercised and dosage reduction may be required when using gliclazide in patients with impaired hepatic function.
Treatment with miconazole (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
Pregnancy and lactation (see Section 4.6 Fertility, Pregnancy and Lactation).

4.4 Special Warnings and Precautions for Use

Acute complications such as severe trauma, fever, infection or surgery.

These acute complications provoke additional metabolic stress which accentuate the predisposition to hyperglycaemia and ketosis. Patients presenting with such conditions may require insulin to maintain control. It is not appropriate to increase the dosage of gliclazide.

Hypoglycaemia.

Close observation and careful initiation and adjustment of dosage are mandatory in patients who are elderly and debilitated, malnourished, semistarved or simply neglecting dietary restrictions. In such patients severe hypoglycaemia may occur with all sulfonylureas and may require corrective therapy over a period of several days. Certain conditions such as alcoholism, insulinoma, adrenal thyroid and pituitary insufficiency increase the sensitivity to sulfonylureas and may dispose to hypoglycaemia.
Careful selection of patients and of the dose used, as well as provision of adequate information to the patient are necessary to avoid hypoglycaemic episodes.
The following factors may increase the risk of hypoglycaemia:
patient does not follow the doctor's treatment advice (particularly elderly patients);
malnutrition;
irregular mealtimes, skipping meals, periods of fasting or dietary changes;
imbalance between physical exercise and carbohydrate intake;
renal impairment;
severe hepatic impairment;
overdose of anti-diabetic agents;
certain endocrine disorders: thyroid disorders, hypopituitarism and adrenal impairment, concomitant administration of certain other medicines (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
Gliclazide should only be prescribed if the patient is likely to have a regular food intake (including breakfast). It is important to have a regular carbohydrate intake due to the increased risk of hypoglycaemia if a meal is delayed, an inadequate amount of food is consumed or the food is low in carbohydrate. Hypoglycaemia is more likely to occur during periods of low-calorie diet, following prolonged or strenuous exercise, following alcohol intake or during treatment with a combination of hypoglycaemic agents.

Poor blood glucose control.

Blood glucose control in treated patients may be affected by St. John's wort (Hypericum perforatum) preparations (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions), fever, trauma, infection or surgical intervention. It may be necessary to discontinue treatment and to administer insulin in these cases.
The efficacy of oral antidiabetic agents often decreases in the long-term. This may be due to progression in the severity of the diabetes, or to a reduced response to treatment. This phenomenon is known as secondary failure and should be distinguished from primary failure, when the drug is ineffective as first-line treatment. However, before classifying the patient as a secondary failure, dose adjustment and reinforcement of dietary measures should be considered.

Unstable blood glucose level (dysglycaemia).

Disturbances in blood glucose, including hypoglycaemia and hyperglycaemia have been reported, in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Indeed, careful monitoring of blood glucose is recommended in all patients receiving gliclazide and a fluoroquinolone at the same time.

Renal and hepatic impairment.

Severe renal or hepatic impairment may affect the distribution of gliclazide and hepatic impairment may also reduce the capacity for neoglucogenesis. These two effects increase the risk of severe hypoglycaemic reactions. A hypoglycaemic episode in these patients may be prolonged and appropriate management should be initiated.

Glucose-6-phosphate dehydrogenase deficiency (G6PD).

Treatment of patients with G6PD-deficiency with sulphonylurea agents can lead to haemolytic anaemia. Since gliclazide belongs to the chemical class of sulphonylurea drugs, caution should be used in patients with G6PD-deficiency and a non-sulphonylurea alternative should be considered.

Lactose intolerance.

Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose galactose malabsorption, or the Lapp lactase deficiency should not take this medicinal product.

Monitoring of diabetic state.

As with other antidiabetic therapies, patients must be under close medical supervision. Particular care must be taken during the initial period of stabilisation. Patients treated with gliclazide should be monitored regularly to ensure optimal control of the diabetic state, and, where necessary, for adjustment of dosage.

Transferring to gliclazide.

Patients who have been previously treated with sulfonylureas or biguanides alone or in combination may be transferred to gliclazide. When gliclazide is administered as sole therapy to patients who have previously required combination therapy (e.g. biguanides and sulfonylureas), careful observation is essential during the transitional phase.
It is not generally recommended that insulin treated patients be transferred to gliclazide.

Patient awareness.

Comprehensive instructions must be given to the patient about the nature of the disease and what must be done to detect and prevent complications.

Patients with porphyria.

Cases of acute porphyria have been described with this class of sulfonylurea drugs, in patients who have porphyria.

Use in the elderly.

No information available.

Paediatric use.

Not recommended for paediatric use, see Section 4.2 Dose and Method of Administration.

Effects on laboratory tests.

Glycated haemoglobin should be monitored regularly. Blood glucose measurement may also be useful.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Disturbances of blood sugar control.

As with all hypoglycaemics, caution should be observed in administering thiazide diuretics to patients on gliclazide therapy, since thiazides have been reported to aggravate the diabetic state. Other drugs which may adversely affect blood sugar control with hypoglycaemic agents in some patients include barbiturates, glucocorticoids and estrogens.
Potentiation of the blood glucose lowering effect and therefore in some instances, hypoglycaemia may occur when one of the following medications is taken.
Blood glucose monitoring during and after treatment is necessary when gliclazide is used with medicines which can interact with gliclazide. It may also be necessary to adjust the dose of gliclazide during and after treatment with such medicines.

1) The following medications are likely to increase the risk of hypoglycaemia.

Concomitant use which is contraindicated.

Miconazole (systemic route, oromucosal gel).

Increases the hypoglycaemic effect with possible onset of hypoglycaemia symptoms, or even coma.
Concomitant use which is not recommended.

Phenylbutazone (systemic route).

Increases the hypoglycaemic effect of sulphonylureas (displaces their binding to plasma proteins and/or reduces their elimination).
It is preferable to use a different anti-inflammatory agent, or else to warn the patient and emphasise the importance of self-monitoring. Where necessary, adjust the dose during and after treatment with the anti-inflammatory agent.

Alcohol.

Acute alcohol intoxication potentiates the hypoglycaemic action of all sulfonylurea by inhibiting compensatory reactions. This can lead to the onset of hypoglycaemic coma. Furthermore, ingestion of alcohol may cause a disulfiram-like reaction with characteristic flushing of the face, throbbing headache, giddiness, tachypnoea, tachycardia or angina pectoris.
Chronic alcohol abuse may, as a result of liver enzyme induction, stimulate the metabolism of sulfonylurea drugs and shorten plasma half-life and duration of action.
Avoid alcohol or medicines containing alcohol.
Concomitant use which requires special care. Potentiation of the blood glucose lowering effect and therefore in some instances, hypoglycaemia may occur when one of the following medications is taken.
Other antidiabetic agents (insulin, acarbose, biguanides, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists) sulfonamides, clarithromycin, oxyphenbutazone, phenylbutazone, clofibrate, salicylates (high doses), coumarin derivatives, chloramphenicol, monoamine oxidase inhibitors (MAOIs), beta-blockers, H2-receptor antagonists, ACE inhibitors, cimetidine, fluconazole and nonsteroidal anti-inflammatory agents, and ethanol.

2) The following medications may cause an increase in blood glucose levels.

Advise the patient and emphasise the importance of glucose monitoring.
Concomitant use which is not recommended.

Danazol.

If the use of danazol cannot be avoided, it may be necessary to adjust the dose of gliclazide during and after treatment with danazol.
Concomitant use which requires special care.

Chlorpromazine.

High doses (> 100 mg per day of chlorpromazine) can increase blood glucose levels (reduced insulin release). Advise the patient and emphasise the importance of glucose monitoring. It may be necessary to adjust the dose of gliclazide during and after treatment with chlorpromazine.

Glucocorticoids (systemic and local route: intra-articular, cutaneous and rectal preparations) and tetracosactrin.

Concomitant use may increase blood glucose levels with possible ketosis (glucocorticoids cause reduced tolerance to carbohydrates). Emphasise the importance of blood glucose monitoring, particularly at the start of treatment. It may be necessary to adjust the dose of gliclazide during and after treatment with glucocorticoids.

Salbutamol, terbutaline (intravenous).

May cause increased blood glucose levels due to beta-2 agonist effects. If necessary, switch to insulin.

Barbiturates, estrogens and progestogens.

May adversely affect blood sugar control with hypoglycaemic agents in some patients by causing increased blood glucose levels.

St John's wort (Hypericum perforatum) preparations.

Gliclazide exposure is decreased by St John's wort (Hypericum perforatum).

3) The following products may cause unstable blood glucose.

Concomitant use which requires special care.

Fluoroquinolones.

In case of a concomitant use of gliclazide and a fluoroquinolone, the patient should be warned of the risk of unstable blood glucose, and the importance of blood glucose monitoring should be emphasised.
Concomitant use to be taken into consideration.

Anticoagulant therapy (warfarin).

Sulphonylureas may lead to potentiation of anticoagulation during concurrent treatment. Adjustment of warfarin may be necessary.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category C)
In animal studies embryo-toxicity and/or birth defects have been demonstrated with some sulfonylureas.
It is important to achieve strict normoglycaemia during pregnancy. Oral hypoglycaemic agents should be replaced by insulin.
The sulfonylureas may enter the fetal circulation and cause neonatal hypoglycaemia.
Gliclazide should not be used in pregnant women.
Gliclazide is contra-indicated during pregnancy and insulin is the drug of first choice for treatment of diabetes during pregnancy. Treatment should be changed from gliclazide to insulin therapy before pregnancy is attempted, or as soon as pregnancy is discovered. Control of diabetes should be achieved before the time of conception to reduce the risk of congenital abnormalities linked to uncontrolled diabetes.
It is not known whether gliclazide or its metabolites are excreted in breast milk. Given the risk of neonatal hypoglycaemia, gliclazide is contra-indicated in women who are breast feeding. A risk to newborns/infants cannot be excluded.
Gliclazide should not be used during lactation.

4.7 Effects on Ability to Drive and Use Machines

Patients should be made aware of the symptoms of hypoglycaemia and should be careful if driving or operating machinery, especially at the beginning of treatment.

4.8 Adverse Effects (Undesirable Effects)

Adverse reactions have occurred in some 12% of cases in clinical studies. However, approximately 2% of patients were withdrawn from therapy because of adverse reactions, notably hypoglycaemia, gastrointestinal disturbances (constipation, nausea, epigastric discomfort and heartburn), dermatological reactions (rash and transient itching), and biochemical abnormalities (elevated serum creatinine, increased serum alkaline phosphatase, raised serum AST, elevated BUN and raised serum bilirubin). Headache, slight disulfiram-like reactions and lassitude have also been reported.
Serious reactions which have been reported with other sulfonylureas are leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, cholestatic jaundice and gastrointestinal haemorrhage. These reactions have not been reported with gliclazide.

Hypoglycaemia.

(See Section 4.4 Special Warnings and Precautions for Use; Section 4.9 Overdose.)
The most frequent adverse reaction with gliclazide is hypoglycaemia.
As is the case with all sulphonylurea drugs, hypoglycaemic reactions have been reported following gliclazide administration. However, a number of studies have shown that hypoglycaemia is less common with gliclazide than with glibenclamide.
Possible symptoms of hypoglycaemia are: headache, intense hunger, nausea, vomiting, lassitude, sleep disorders, agitation, aggression, poor concentration, reduced awareness and slowed reactions, depression, confusion, visual and speech disorders, aphasia, tremor, paresis, sensory disorders, dizziness, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness and loss of consciousness, possibly resulting in coma and/or death. In addition, signs of adrenergic counter-regulation may be observed: sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmia.
Usually, symptoms disappear after intake of carbohydrate such as sugar (artificial sweeteners have no effect). Experience with other sulphonylureas shows that hypoglycaemia can recur even when these measures are initially effective. If a hypoglycaemic episode is severe or prolonged, and even if it is temporarily controlled by intake of sugar, immediate medical treatment or even hospitalisation is required.
As is the case with all forms of antidiabetic therapy, hypoglycaemic reactions have occasionally been reported following gliclazide administration.
Severe hypoglycaemia, though very rarely reported, may occur in patients receiving gliclazide.

Other adverse effects reported with gliclazide.

Gastrointestinal disturbances (reported with gliclazide), including nausea, dyspepsia, diarrhoea, abdominal pain, vomiting and constipation may be avoided or minimised if gliclazide is taken with breakfast.
The following adverse effects have been rarely reported:

Skin and subcutaneous tissue disorders.

Pruritus, urticaria, maculopapular rashes, rash, angioedema, erythema and bullous reactions (such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) (as with other sulfur-containing medications) and autoimmune bullous disorders and exceptionally, drug rash with eosinophilia and systemic symptoms (DRESS).

Blood and lymphatic system disorders (as with other sulphonylurea medications).

Anaemia, leucopenia, thrombocytopenia and agranulocytosis. These are in general reversible upon discontinuation of medication.

Hepatobiliary disorders.

Elevations of serum bilirubin and hepatic enzymes (AST, ALT, alkaline phosphatase) levels, and exceptionally, hepatitis (isolated reports). Treatment should be discontinued if cholestatic jaundice appears. These symptoms usually disappear after discontinuation of treatment.

Investigations.

Occasional elevations of serum creatinine, blood urea nitrogen.

Eye disorders.

Transient visual disturbances may occur due to changes in blood glucose levels, particularly on initiation of treatment. As with any glucose-lowering medication, transient visual disturbances may occur on initiation of treatment due to changes in blood glucose levels.

Class effects.

The following adverse events have been observed with sulphonylureas: cases of erythrocytopenia, agranulocytosis, haemolytic anaemia, pancytopenia and allergic vasculitis, hyponatremia, elevated liver enzyme levels and even impairment of liver function (e.g. with cholestasis and jaundice) and hepatitis which regressed after withdrawal of the sulphonylurea or led to life-threatening liver failure in isolated cases.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Overdose of sulphonylureas may cause hypoglycaemia.
Moderate symptoms of hypoglycaemia (without loss of consciousness or neurological signs), should be corrected by carbohydrate intake, dose adjustment and/or modification of diet. Strict monitoring should be continued until the doctor is sure that the patient is out of danger.
Severe hypoglycaemic reactions are possible (with coma, convulsions or other neurological disorders) and must be treated as a medical emergency, requiring immediate hospitalisation.
If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid I.V. injection of 50 mL of concentrated glucose solution (20 to 30%). This should be followed by continuous infusion of a more dilute glucose solution (10%) at a rate necessary to maintain blood glucose levels above 5 mmol/L. It is recommended that patients should be monitored closely for a 48 hour period at least.
Plasma clearance of gliclazide may be prolonged in patients with hepatic disease. However, due to the strong binding of gliclazide to proteins, dialysis is not effective in these patients.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Mode of action.

Gliclazide stimulates insulin secretion from functional pancreatic β-cells and increases the sensitivity of the β-cells to a glucose stimulus (some residual β-cell function is therefore necessary). Gliclazide restores the diminished first phase of insulin secretion noted in noninsulin dependent diabetes mellitus.
Any long-term hypoglycaemic activity of gliclazide can be attributed to an ability to maintain its effect on insulin secretion. Extrapancreatic effects may also be involved in the long-term efficacy of gliclazide. Extrapancreatic effects demonstrated for gliclazide include improvement in insulin mediated glucose utilisation and potentiation of postreceptor insulin sensitive pathways.
At normal therapeutic doses in humans, gliclazide reduces platelet adhesiveness and aggregation.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

Gliclazide is absorbed in the gastrointestinal tract reaching peak serum concentrations within four to six hours.
Single dose studies have demonstrated that maximal falls in blood glucose levels (23% of an 80 mg dose; 30% of a 160 mg dose) occur approximately five hours after drug administration; nine hours after a dose of 160 mg, a reduction of 20% was still in evidence.
The half-life of gliclazide is approximately twelve hours.

Distribution.

Gliclazide is distributed to the extracellular fluid. In animals, high concentrations of the drug were found in the liver, kidneys, skin, lungs, skeletal muscle, intestinal and cardiac tissue. Penetration of gliclazide into the central nervous system was negligible. Gliclazide crosses the placental barrier and penetrates the fetus. The apparent volume of distribution of gliclazide (20 to 40% expressed as a percentage bodyweight) is low and probably reflects the high degree of protein binding (94.2% at a plasma concentration of approximately 8 microgram/mL).

Metabolism.

Little information is available on the metabolism of gliclazide. At least eight metabolites (three major) have been observed by thin layer and gas liquid chromatography. Some of these are glucuronic acid conjugates; only one of the metabolites has been identified (para-toluene sulfonamide). The liver is the probable site of metabolism.

Excretion.

Approximately 70% of the administered dose appears to be excreted in the urine and 11% in the faeces. The urinary excretion of the drug is slow and the maximum rates do not occur until seven to ten hours after initial administration. The metabolic products are detectable in the urine 120 hours after oral administration. Faecal elimination is usually complete within 144 hours of oral administration.

5.3 Preclinical Safety Data

Genotoxicity.

In animal studies embryotoxicity and/or birth defects have been demonstrated.

Carcinogenicity.

No animal studies have been performed that investigate the carcinogenic potential of gliclazide.

6 Pharmaceutical Particulars

6.1 List of Excipients

The tablets also contain the following excipients: lactose monohydrate, microcrystalline cellulose, povidone, purified talc, sodium starch glycollate type A and magnesium stearate. The tablets are gluten free.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 30°C.

6.5 Nature and Contents of Container

Blister (AL/PVC/PVDC) packs 100's.
Bottle (HDPE/PE)* packs 100's.
*Bottle packs are not currently marketed in Australia.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Gliclazide is a white or almost white powder, practically insoluble in water, freely soluble in dichloromethane, sparingly soluble in acetone and slightly soluble in ethanol 96%.
Gliclazide. The chemical name for gliclazide is 1-(3-azabicyclo[3.3.0] oct- 3-yl)-3-para- tolylsulfonylurea.

Molecular formula.

C15H21N3O3S.

Molecular weight.

323.4.

Chemical structure.

Its structural formula is:

CAS number.

21187-98-4.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes